Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Kiora Pharmaceuticals (NASDAQ: KPRX) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 3:20 p.m. ET.
A live webcast will be available on the company's investor relations website ir.kiorapharma.com, with a replay accessible for approximately 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – KPRX
In the Feb 19 session, KPRX declined 1.44%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 27 | Advisory board addition | Positive | -0.5% | Retinal specialist joined Scientific Advisory Board to guide retinal strategy. |
| Dec 01 | Patent and trial update | Positive | -2.5% | New U.S. patent on KIO-100 formulations and active Phase 2 KLARITY trial. |
| Nov 07 | Earnings and pipeline | Positive | +0.4% | Q3 2025 results, cash position, and progress in two Phase 2 retinal trials. |
| Oct 30 | Consortium collaboration | Positive | +0.8% | Joined RARE-X Vision Consortium to support rare ocular disorder research. |
| Oct 15 | Conference participation | Neutral | -0.7% | Participation in ophthalmology-focused investor and industry events. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive corporate and pipeline updates have not consistently driven upside, with several constructive announcements followed by flat or negative 24h moves.
Over the past several months, Kiora reported multiple developments, including joining the RARE-X Vision Consortium on Oct 30, 2025 and appointing retinal expert Dr. Taiji Sakamoto to its Scientific Advisory Board on Jan 27, 2026. It advanced retinal programs with two ongoing Phase 2 trials and highlighted cash runway into late 2027 in Q3 2025 results. A U.S. patent on KIO-100 formulations and ongoing KLARITY Phase 2 enrollment were also noted. Against this backdrop, the new conference participation fits a pattern of ongoing investor and scientific outreach.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 3:20 p.m. ET.
A live webcast will be available on Kiora's investor relations website, ir.kiorapharma.com, on the IR homepage and under the News & Events section. A replay of the webcast will be available for approximately 90 days.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH). KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration.
In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts.
Contacts:
Investors
investors@kiorapharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/284505